Use of a multi-gene pharmacogenetic panel reduces adverse drug effects
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved..
Swen et al.1 examine the utility of multi-gene pharmacogenetic testing in a large multi-national cohort. They show fewer adverse drug reactions among patients receiving testing and prescribing recommendations based on genotype results compared with those receiving usual care.
| Errataetall: |
CommentOn: Lancet. 2023 Feb 4;401(10374):347-356. - PMID 36739136 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Cell reports. Medicine - 4(2023), 5 vom: 16. Mai, Seite 101021 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cavallari, Larisa H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 19.05.2023 Date Revised 28.05.2023 published: Print-Electronic CommentOn: Lancet. 2023 Feb 4;401(10374):347-356. - PMID 36739136 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.xcrm.2023.101021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355884909 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355884909 | ||
| 003 | DE-627 | ||
| 005 | 20231226065306.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xcrm.2023.101021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM355884909 | ||
| 035 | |a (NLM)37084734 | ||
| 035 | |a (PII)S2666-3791(23)00131-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cavallari, Larisa H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of a multi-gene pharmacogenetic panel reduces adverse drug effects |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.05.2023 | ||
| 500 | |a Date Revised 28.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Lancet. 2023 Feb 4;401(10374):347-356. - PMID 36739136 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Swen et al.1 examine the utility of multi-gene pharmacogenetic testing in a large multi-national cohort. They show fewer adverse drug reactions among patients receiving testing and prescribing recommendations based on genotype results compared with those receiving usual care | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Comment | |
| 700 | 1 | |a Johnson, Julie A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports. Medicine |d 2020 |g 4(2023), 5 vom: 16. Mai, Seite 101021 |w (DE-627)NLM310587662 |x 2666-3791 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2023 |g number:5 |g day:16 |g month:05 |g pages:101021 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xcrm.2023.101021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2023 |e 5 |b 16 |c 05 |h 101021 | ||